February 16, 2012 / 12:57 PM / in 6 years

UPDATE 1-Paladin Labs posts higher 4th-qtr profit

Feb 16 (Reuters) - Canadian specialty pharmaceuticals company Paladin Labs Inc posted a higher fourth-quarter profit helped by increased sales of certain key drugs.

The Montreal-based company expects full-year revenue of at least C$140 million.

For the October-December quarter, net income was C$15.8 million, or 76 Canadian cents a share, up from C$13.9 million, or 71 Canadian cents a share, a year ago.

Revenue rose about 14 percent to C$37.1 million.

Total sales of drugs Tridural, Trelstar, Testim, Metadol, and Plan B increased 10 percent for the quarter, the company said in a statement.

Shares of Paladin closed at C$45.15 on Wednesday on the Toronto Stock Exchange.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below